Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism

Table 5 Observed outcomes until end of follow-up in January 2009 (n = 85)

	Nodule in US		P	RR (95%CI)
	No (n = 32)	Yes (n = 53)
Deceased
No	29 (90.6%)	41 (77.4%)	0.1202	1.00
Yes	3 (9.4%)	12 (22.6%)		2.83 (0.73; 10.93)
Transplant
No	28 (87.5%)	48 (90.6%)	0.7232	1.37 (0.54; 5.53)
Yes	4 (12.5%)	5 (9.4%)		1.00
Cardiovascular and/or cerebrovascular event4
No	25 (78.1%)	43 (81.1%)	0.7371	1.20 (0.41; 3.56)
Yes	7 (21.9%)	10 (18.9%)		1.00
Vascular calcification5
No	23 (71.9%)	33 (62.3%)	0.6331	1.00
Yes	7 (21.9%)	13 (24.5%)		1.29 (0.40; 4.28)
No register	2 (6.3%)	7 (13.2%)
Bone disease6
No	18 (56.3%)	34 (64.2%)	0.2021	1.89 (0.63; 5.56)
Yes	12 (37.5%)	12 (22.6%)		1.00
No register	2 (6.3%)	7 (13.2%)
Surgery
No	32 (100%)	37 (69.8%)	< 0.001	3
Yes	0 (0%)	16 (30.2%)

¹Pearson’s χ²;

²Fisher’s exact test;

³It was not possible to calculate OR due to null cases;

⁴Patients’ records: Acute myocardial infarct, acute coronary syndrome, unstable angina, acute arterial occlusion, congestive heart failure, abnormal findings in heart catheterism, coronary angioplasty and myocardial and coronary angioplasty and myocardial revascularization;

⁵Vascular calcification in imaging (ultrasonography, computed tomography or plain radigraphies);

⁶Imaging or notes on them, with evidence of bone disease attributed to SHPT, and bone deformities or fractures attributed to the disease. US: Ultrasonography; SPTH: Secondary hyperparathyroidism.